Clene (NASDAQ: CLNN) to Present at Canaccord Genuity 44th Annual Growth Conference
Clene (NASDAQ: CLNN) to present at Canaccord Genuity 44th Annual Growth Conference. Learn about the company's focus on treating ALS and MS. Watch the live webcast for valuable insights.
This news highlights Clene's commitment to developing innovative therapies for neurodegenerative diseases. Investors and individuals impacted by ALS and MS may gain valuable insights from the company's presentation.